When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
![]() 4AB 2 months ago | Other | €1.4 Per Share |
![]() 4AB 5 months ago | Other | €1.4 Per Share |
![]() 4AB 8 months ago | Other | €1.32 Per Share |
![]() 4AB 11 months ago | Other | €1.32 Per Share |
![]() 4AB 12 Apr 2024 | Other | €1.32 Per Share |
31 Jul 2025 (In 3 weeks) Date | | 3.18 Cons. EPS | - EPS |
24 Jul 2025 (In 2 weeks) Date | | 3.18 Cons. EPS | - EPS |
23 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | - Cons. EPS | - EPS |
![]() 4AB 2 months ago | Other | €1.4 Per Share |
![]() 4AB 5 months ago | Other | €1.4 Per Share |
![]() 4AB 8 months ago | Other | €1.32 Per Share |
![]() 4AB 11 months ago | Other | €1.32 Per Share |
![]() 4AB 12 Apr 2024 | Other | €1.32 Per Share |
31 Jul 2025 (In 3 weeks) Date | | 3.18 Cons. EPS | - EPS |
24 Jul 2025 (In 2 weeks) Date | | 3.18 Cons. EPS | - EPS |
23 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Robert A. Michael CPA CEO | XBER Exchange | US00287Y1091 ISIN |
US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.